Document Auto Tags
Document Information
Title: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Source: https://storage.googleapis.com/polarys-documents/uploads/cd736e98-5c9c-4350-b76f-962be56a1f6b.txt
Content Type: press_release
Word Count: 2083
Applied Auto Tags
| Auto Tag | Description | Extracted Value | Confidence | Applied | Actions |
|---|---|---|---|---|---|
| Communication Type | No description | Press Release | N/A | N/A | |
| CEO | No description | Christopher Viehbacher | N/A | N/A | |
| Company | No description | Biogen | N/A | N/A | |
| Executives | No description | Travis Murdoch | N/A | N/A | |
| CEO | No description | The most prominent company mentioned in the document is Biogen Inc. The document is dated June 30, 2025., According to multiple sources, Christopher A. Viehbacher was the President and Chief Executive Officer of Biogen Inc. in November 2022 and continued in this role through June 2025 and beyond. He joined Biogen as President and Chief Executive Officer and a member of the Board of Directors in November 2022., Christopher Viehbacher | N/A | N/A |
About Auto Tags
Automatic Extraction
Auto tags use AI to automatically extract specific information from this document based on predefined rules.
Re-apply Tags
You can re-apply auto tags to get updated extractions if the auto tag rules have been modified.
Remove Tags
Remove individual auto tags or use "Remove All Tags" to bulk remove all applied tags at once.